Obesity, and especially visceral adiposity, escalates the development of insulin resistance and type 2 diabetes. Excess adipose tissue contributes to a chronic increase in circulating fatty acids reducing the usage of glucose as a source of cellular energy. Excess fatty acids also result in increased deposition of fat in muscle and liver, and increased metabolites such as diacylglycerol and ceramide which activate isoforms of protein kinase C that impede cellular insulin signalling. Chronically raised lipid levels also impair islet beta cell function, acting in conjuction with insulin resistance to aggravate hyperglycaemia. The detrimental effects of several adipokines such as TNFα, IL6 and RBP4, which are produced in excess by an increased adipose mass, and reduced production of adiponectin are further mechanisms through which obesity potentiates the development of type 2 diabetes.
Chan JM, Stampfer MJ, Ribb EB et al. Obesity, fat distribution and weight gain as risk factors for clinical diabetes in man. Diabetes Care1994;17:961-9.
2.
Colditz GA, Willett WC, Rotnitzky A., Manson JEWeight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med1995;122:481-6.
3.
Hu FB, Manson JE, Stampfer MJ et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women . N Engl J Med2001;345:730-37.
4.
Must A., Spandano J., Coakley EH et al. The disease burden associated with overweight and obesity. JAMA1999;282:153-9.
5.
Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA2003; 289:76-9.
6.
Bray GA, Jablonski KA, Fujimoto WY et al. Relation of central adiposity and body mass index to the development of diabetes in the Diabetes Prevention Program. Am J Clin Nutr2008;87:1212-8.
7.
Barnett AH, Dixon AN, Bellary S. et al. Type 2 diabetes and cardiovascular risk in the UK South Asian community . Diabetologia2006;49:2234-46.
WHO expert consultation.Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet2004;363:157-63.
10.
The Emerging Risk Factor Collaboration.Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies . Lancet2011;377:1085-95.
11.
Montague CT , O’Rahilly S.The perils of portliness: causes and consequences of visceral adiposity. Diabetes2000;49:883-8.
12.
Thorleifsson G., Walters GB, Gudbjartsson DF et al. Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat Genet2009;41:18-24.
13.
O’Rahilly S.Human genetics illuminates the paths to metabolic disease. Nature2009;402:307-14.
14.
McGarry JDDysregulation of fatty acid metabolism in the etiology of type 2 diabetes . Diabetes2002;51:7-18.
15.
Boden G.Obesity, insulin resistance, type 2 diabetes and free fatty acids. Exp Rev Enocrinol Metab2006;1:499-505.
16.
Groop LC, Bonadonna RC, Del Prato S. et al. Glucose and FFA metabolism in non-insulin dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest1989;84:205-15.
17.
Shulman GICellular mechanisms of insulin resistance. J Clin Invest2000;106:171-6.
18.
Kahn BB, Flier JSObesity and insulin resistance. J Clin Invest2000;106:473-81.
19.
Saltiel AR, Kahn CRInsulin signalling and the regulation of glucose and lipid metabolism. Nature2001;414:799-806.
20.
DeFronzo RAThe triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes1988;37:667-87.
21.
Kahn SE, Hull RL, Utzschneider KMMechanisms linking obesity to insulin resistance and type 2 diabetes. Nature2006;444:840-6.
22.
Kotronen A. , Juurinen L., Tiikkainen M. et al. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes . Gastroenterology2008;135:122-390.
23.
Frayn KNAdipose tissue as a buffer for daily lipid flux. Diabetologia2002;45:1201-10.
24.
Rube H., Lehrke M., Parhofer KG, Broedi UCAdipokines and insulin resistance. Molecular Med2008;14:741-51.
25.
Antuna-Puente B., Feve B., Fellahi S., Bastard JPAdipokines: the missing link between insulin resistance and obesity. Diabetes Metab2008 ;34:2-11.
26.
Graham TE, Yang Q., Bluher M. et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med2006;354:2552-63.
27.
Sul HSResistin/ADSF/FIZZ3 in obesity and diabetes. Trends Endocrinol Metab2004;15:247-9.
28.
Kadowaki T. , Yamauchi T.Adiponectin and adiponectin receptors. Endocr Revs2005;26:439-51.
29.
Tomlinson JW , Walker EA, Bujalska IJ et al. 11 beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Revs2004;25:831-66.
30.
Kahn SEThe relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia2003;46:3-19.
31.
Butler A., Janson J., Bonner-Weir S., Butler P.B-cell deficit and increased b-cell apoptosis in humans with type 2 diabetes . Diabetes2003; 52:102-10.
32.
Sladek R., Rocheleau G., Rung J. et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature2007;445:881-5.
33.
Unger RH, Zhou YTLipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover . Diabetes2001;50 (suppl 1):S118-21.
34.
Kulkarni RN , Wang ZI, Wang EM et al. Leptin rapidly suppresses insulin release from insulinoma cells rat and human islets and in vivo in mice. J Clin Invest1997;100:2729-36.
35.
Thorens B.Glucose sensing and the pathogenesis of obesity and type 2 diabetes. Int J Obes2008;32 (Suppl6):S62-71.
